These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 24071736)

  • 21. [The binding of bispecific monoclonal antibodies to the solid phase-adsorbed antigens].
    Dmitriev DA; Massino IuS; Smirnova MB; Segal OL; Pavlova EB; Koliaskina GI; Osipov AP; Egorov AM; Dmitriev AD
    Bioorg Khim; 2001; 27(4):265-74. PubMed ID: 11558260
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin.
    Müller D; Karle A; Meissburger B; Höfig I; Stork R; Kontermann RE
    J Biol Chem; 2007 Apr; 282(17):12650-60. PubMed ID: 17347147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair.
    Strop P; Ho WH; Boustany LM; Abdiche YN; Lindquist KC; Farias SE; Rickert M; Appah CT; Pascua E; Radcliffe T; Sutton J; Chaparro-Riggers J; Chen W; Casas MG; Chin SM; Wong OK; Liu SH; Vergara G; Shelton D; Rajpal A; Pons J
    J Mol Biol; 2012 Jul; 420(3):204-19. PubMed ID: 22543237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of different interchain linkers on biological activity of an anti-prostate cancer single-chain bispecific antibody.
    Hao CH; Han QH; Shan ZJ; Hu JT; Zhang N; Zhang XP
    Theor Biol Med Model; 2015 Aug; 12():14. PubMed ID: 26246000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Production of bispecific antibodies in "knobs-into-holes" using a cell-free expression system.
    Xu Y; Lee J; Tran C; Heibeck TH; Wang WD; Yang J; Stafford RL; Steiner AR; Sato AK; Hallam TJ; Yin G
    MAbs; 2015; 7(1):231-42. PubMed ID: 25427258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of biparatopic bispecific antibody possessing tetravalent scFv-Fc capable of binding to ROBO1 expressed in hepatocellular carcinoma cells.
    Watanabe Y; Tanabe A; Hamakubo T; Nagatoishi S; Tsumoto K
    J Biochem; 2021 Oct; 170(2):307-315. PubMed ID: 33844018
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A modular IgG-scFv bispecific antibody topology.
    Orcutt KD; Ackerman ME; Cieslewicz M; Quiroz E; Slusarczyk AL; Frangioni JV; Wittrup KD
    Protein Eng Des Sel; 2010 Apr; 23(4):221-8. PubMed ID: 20019028
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A bispecific transmembrane antibody simultaneously targeting intra- and extracellular epitopes of the epidermal growth factor receptor inhibits receptor activation and tumor cell growth.
    Müller N; Hartmann C; Genssler S; Koch J; Kinner A; Grez M; Wels WS
    Int J Cancer; 2014 Jun; 134(11):2547-59. PubMed ID: 24243620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Engineered hapten-binding antibody derivatives for modulation of pharmacokinetic properties of small molecules and targeted payload delivery.
    Dengl S; Sustmann C; Brinkmann U
    Immunol Rev; 2016 Mar; 270(1):165-77. PubMed ID: 26864111
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulation of antibody response in vitro. IX. Induction of secondary anti-hapten IgG antibody response by anti-immunoglobulin and enhancing soluble factor.
    Kishimoto T; Ishizaka K
    J Immunol; 1975 Feb; 114(2 Pt 1):585-91. PubMed ID: 1079034
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The comparison of the ability of monoclonal antibodies directed to different proteins (human IgG, human myoglobin and HRP) and bispecific antibodies derived thereof to bind antigens immobilized on a surface of a solid phase.
    Dmitriev DA; Massino YS; Segal OL; Smirnova MB; Kolyaskina GI; Pavlova EV; Osipov AP; Egorov AM; Dmitriev AD
    Clin Chim Acta; 2001 Jul; 309(1):57-71. PubMed ID: 11408007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of the binding of bispecific monoclonal antibodies with immobilized antigens (human IgG and horseradish peroxidase) using a resonant mirror biosensor.
    Dmitriev DA; Massino YS; Segal OL; Smirnova MB; Pavlova EV; Gurevich KG; Gnedenko OV; Ivanov YD; Kolyaskina GI; Archakov AI; Osipov AP; Dmitriev AD; Egorov AM
    J Immunol Methods; 2002 Mar; 261(1-2):103-18. PubMed ID: 11861069
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Construction and production of an IgG-Like tetravalent bispecific antibody, IgG-single-chain Fv fusion.
    Lu D; Zhu Z
    Methods Mol Biol; 2014; 1060():185-213. PubMed ID: 24037843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells.
    Asano R; Watanabe Y; Kawaguchi H; Fukazawa H; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
    J Biol Chem; 2007 Sep; 282(38):27659-65. PubMed ID: 17644522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bispecific Antibody Armed T Cells to Target Cancer Cells.
    Thakur A; Lum LG; Mittal S
    Methods Mol Biol; 2018; 1722():117-126. PubMed ID: 29264802
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generation and characterization of a novel tetravalent bispecific antibody that binds to hepatitis B virus surface antigens.
    Park SS; Ryu CJ; Kang YJ; Kashmiri SV; Hong HJ
    Mol Immunol; 2000 Dec; 37(18):1123-30. PubMed ID: 11451417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells.
    Guettinger Y; Barbin K; Peipp M; Bruenke J; Dechant M; Horner H; Thierschmidt D; Valerius T; Repp R; Fey GH; Stockmeyer B
    J Immunol; 2010 Feb; 184(3):1210-7. PubMed ID: 20042573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance.
    Yazaki PJ; Lee B; Channappa D; Cheung CW; Crow D; Chea J; Poku E; Li L; Andersen JT; Sandlie I; Orcutt KD; Wittrup KD; Shively JE; Raubitschek A; Colcher D
    Protein Eng Des Sel; 2013 Mar; 26(3):187-93. PubMed ID: 23175797
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens.
    Gautherot E; Le Doussal JM; Bouhou J; Manetti C; Martin M; Rouvier E; Barbet J
    J Nucl Med; 1998 Nov; 39(11):1937-43. PubMed ID: 9829586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bispecific single-chain diabody-immunoliposomes targeting endoglin (CD105) and fibroblast activation protein (FAP) simultaneously.
    Rabenhold M; Steiniger F; Fahr A; Kontermann RE; Rüger R
    J Control Release; 2015 Mar; 201():56-67. PubMed ID: 25617725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.